ATXS
Price
$5.44
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
316.03M
43 days until earnings call
CLDX
Price
$20.29
Change
-$0.88 (-4.16%)
Updated
Jun 27 closing price
Capitalization
1.35B
39 days until earnings call
Interact to see
Advertisement

ATXS vs CLDX

Header iconATXS vs CLDX Comparison
Open Charts ATXS vs CLDXBanner chart's image
Astria Therapeutics
Price$5.44
Change-$0.00 (-0.00%)
Volume$50
Capitalization316.03M
Celldex Therapeutics
Price$20.29
Change-$0.88 (-4.16%)
Volume$2.47M
Capitalization1.35B
ATXS vs CLDX Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CLDX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ATXS: $5.44 vs. CLDX: $20.29)
Brand notoriety: ATXS and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 0% vs. CLDX: 251%
Market capitalization -- ATXS: $316.03M vs. CLDX: $1.35B
ATXS [@Biotechnology] is valued at $316.03M. CLDX’s [@Biotechnology] market capitalization is $1.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, CLDX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while CLDX’s TA Score has 3 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • CLDX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than CLDX.

Price Growth

ATXS (@Biotechnology) experienced а -7.17% price change this week, while CLDX (@Biotechnology) price change was -1.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

CLDX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.35B) has a higher market cap than ATXS($316M). CLDX YTD gains are higher at: -19.707 vs. ATXS (-39.150). ATXS has higher annual earnings (EBITDA): -124.4M vs. CLDX (-213.94M). CLDX has more cash in the bank: 673M vs. ATXS (295M). CLDX has less debt than ATXS: CLDX (3.43M) vs ATXS (5.06M). CLDX has higher revenues than ATXS: CLDX (7.56M) vs ATXS (0).
ATXSCLDXATXS / CLDX
Capitalization316M1.35B23%
EBITDA-124.4M-213.94M58%
Gain YTD-39.150-19.707199%
P/E RatioN/AN/A-
Revenue07.56M-
Total Cash295M673M44%
Total Debt5.06M3.43M148%
FUNDAMENTALS RATINGS
ATXS vs CLDX: Fundamental Ratings
ATXS
CLDX
OUTLOOK RATING
1..100
7956
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
5861
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (56) in the Biotechnology industry is in the same range as ATXS (59). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

CLDX's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that CLDX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CLDX's SMR Rating (94) in the Biotechnology industry is in the same range as ATXS (97). This means that CLDX’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (58) in the Biotechnology industry is in the same range as CLDX (61). This means that ATXS’s stock grew similarly to CLDX’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that ATXS’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCLDX
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NBGRY13.430.73
+5.72%
NATIONAL BK GREECE S A
SHVLF0.220.01
+2.64%
Starcore International Mines, Ltd.
BOMXF2.340.04
+1.68%
Bolsa Mexicana de Valores, S.A.B. de C.V.
BCMXY20.15N/A
N/A
Bank of Communications Co. Ltd.
SOMC21.00N/A
N/A
Southern Michigan Bancorp, Inc.

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
N/A
DNLI - ATXS
57%
Loosely correlated
-2.69%
CRNX - ATXS
54%
Loosely correlated
-0.10%
XENE - ATXS
54%
Loosely correlated
+0.62%
TRDA - ATXS
53%
Loosely correlated
-1.57%
APGE - ATXS
52%
Loosely correlated
N/A
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-4.16%
DNLI - CLDX
54%
Loosely correlated
-2.69%
BEAM - CLDX
54%
Loosely correlated
-1.98%
RVMD - CLDX
50%
Loosely correlated
-1.52%
CRNX - CLDX
50%
Loosely correlated
-0.10%
ATXS - CLDX
50%
Loosely correlated
N/A
More